256 related articles for article (PubMed ID: 38025519)
1. Diagnosis and Management of Cardiovascular Risk in Patients with Polycythemia Vera.
Benevolo G; Marchetti M; Melchio R; Beggiato E; Sartori C; Biolé CA; Rapezzi D; Bruno B; Milan A
Vasc Health Risk Manag; 2023; 19():765-778. PubMed ID: 38025519
[TBL] [Abstract][Full Text] [Related]
2. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
[TBL] [Abstract][Full Text] [Related]
3. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
4. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
[TBL] [Abstract][Full Text] [Related]
5. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
[TBL] [Abstract][Full Text] [Related]
6. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
7. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2023 Sep; 98(9):1465-1487. PubMed ID: 37357958
[TBL] [Abstract][Full Text] [Related]
8. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
9. How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.
Reiter A; Harrison C
Curr Hematol Malig Rep; 2016 Oct; 11(5):356-67. PubMed ID: 26894383
[TBL] [Abstract][Full Text] [Related]
10. Polycythemia Vera: Rapid Evidence Review.
Fox S; Griffin L; Robinson Harris D
Am Fam Physician; 2021 Jun; 103(11):680-687. PubMed ID: 34060791
[TBL] [Abstract][Full Text] [Related]
11. Polycythemia Vera.
Spivak JL
Curr Treat Options Oncol; 2018 Mar; 19(2):12. PubMed ID: 29516275
[TBL] [Abstract][Full Text] [Related]
12. Practice Patterns in the Diagnosis and Treatment of Polycythemia Vera in the Post-JAK2 V617F Discovery Era.
Kander EM; Moliterno AR; Rademaker A; Streiff MB; Spivak JL; Stein BL
J Natl Compr Canc Netw; 2016 Oct; 14(10):1238-1245. PubMed ID: 27697978
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular events and intensity of treatment in polycythemia vera.
Marchioli R; Finazzi G; Specchia G; Cacciola R; Cavazzina R; Cilloni D; De Stefano V; Elli E; Iurlo A; Latagliata R; Lunghi F; Lunghi M; Marfisi RM; Musto P; Masciulli A; Musolino C; Cascavilla N; Quarta G; Randi ML; Rapezzi D; Ruggeri M; Rumi E; Scortechini AR; Santini S; Scarano M; Siragusa S; Spadea A; Tieghi A; Angelucci E; Visani G; Vannucchi AM; Barbui T;
N Engl J Med; 2013 Jan; 368(1):22-33. PubMed ID: 23216616
[TBL] [Abstract][Full Text] [Related]
14. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients.
Wehmeier A; Daum I; Jamin H; Schneider W
Ann Hematol; 1991 Aug; 63(2):101-6. PubMed ID: 1912029
[TBL] [Abstract][Full Text] [Related]
15. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
[TBL] [Abstract][Full Text] [Related]
16. Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
Stein BL; Moliterno AR; Tiu RV
Ann Hematol; 2014 Dec; 93(12):1965-76. PubMed ID: 25270596
[TBL] [Abstract][Full Text] [Related]
17. Current management strategies for polycythemia vera and essential thrombocythemia.
Guglielmelli P; Vannucchi AM
Blood Rev; 2020 Jul; 42():100714. PubMed ID: 32546373
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Risk in Polycythemia Vera: Thrombotic Risk and Survival: Can Cytoreductive Therapy Be Useful in Patients with Low-Risk Polycythemia Vera with Cardiovascular Risk Factors?
Mancuso S; Santoro M; Accurso V; Agliastro G; Raso S; Di Piazza F; Perez A; Bono M; Russo A; Siragusa S
Oncol Res Treat; 2020; 43(10):526-530. PubMed ID: 32772025
[TBL] [Abstract][Full Text] [Related]
19. Prognostic risk model for patients with high-risk polycythemia vera and essential thrombocythemia.
Mangaonkar AA; Hoversten KP; Gangat N
Expert Rev Hematol; 2018 Mar; 11(3):247-252. PubMed ID: 29313725
[TBL] [Abstract][Full Text] [Related]
20. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2011 Mar; 86(3):292-301. PubMed ID: 21351120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
